211 related articles for article (PubMed ID: 10954763)
1. Treatment of type II gastric carcinoid tumors with somatostatin analogues.
Tomassetti P; Migliori M; Caletti GC; Fusaroli P; Corinaldesi R; Gullo L
N Engl J Med; 2000 Aug; 343(8):551-4. PubMed ID: 10954763
[No Abstract] [Full Text] [Related]
2. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
3. [Current treatment of carcinoid tumor].
Elizalde I; Borda F
Gastroenterol Hepatol; 2002 Oct; 25(8):508-13. PubMed ID: 12361534
[No Abstract] [Full Text] [Related]
4. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
5. Gastric carcinoid tumors associated with chronic hypergastrinemia in a patient with Zollinger-Ellison syndrome.
Berger MW; Stephens DH
Radiology; 1996 Nov; 201(2):371-3. PubMed ID: 8888225
[TBL] [Abstract][Full Text] [Related]
6. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
7. Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.
Feurle GE
Gut; 1994 Feb; 35(2):275-7. PubMed ID: 8307483
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogs for gastric carcinoids: For many, but not all.
Massironi S; Zilli A; Conte D
World J Gastroenterol; 2015 Jun; 21(22):6785-93. PubMed ID: 26078554
[TBL] [Abstract][Full Text] [Related]
9. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
Rohaizak M; Farndon JR
ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
[TBL] [Abstract][Full Text] [Related]
10. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
12. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
13. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment.
Norton JA; Melcher ML; Gibril F; Jensen RT
Surgery; 2004 Dec; 136(6):1267-74. PubMed ID: 15657586
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in carcinoid pathogenesis, diagnosis and management.
Ganim RB; Norton JA
Surg Oncol; 2000 Dec; 9(4):173-9. PubMed ID: 11476988
[TBL] [Abstract][Full Text] [Related]
15. Gastric carcinoid tumors as a consequence of chronic hypergastrinemia: spiral CT findings.
Ho AC; Horton KM; Fishman EK
Clin Imaging; 2000; 24(4):200-3. PubMed ID: 11274882
[TBL] [Abstract][Full Text] [Related]
16. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
17. Gallbladder and gastric argyrophil carcinoid associated with a case of Zollinger-Ellison syndrome.
Barone GW; Schaefer RF; Counce JS; Eidt JF
Am J Gastroenterol; 1992 Mar; 87(3):392-4. PubMed ID: 1539581
[TBL] [Abstract][Full Text] [Related]
18. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
19. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
20. Well-differentiated gastric carcinoids treated with somatostatin analogues.
Cuesta Hernández M; Gómez Hoyos E; de Miguel Novoa P; Díaz Pérez JÁ
Endocrinol Nutr; 2013 Jan; 60(1):41-3. PubMed ID: 22483381
[No Abstract] [Full Text] [Related]
[Next] [New Search]
